Abstract: Human epidermal growth factor receptor 3 (HER3/ERBB3), a member of the HER family, is widely expressed in a variety of cancers. Activated by the ligand neuregulin, HER3 forms heterodimers mainly with EGFR (ERBB1/HER1) and HER2 (ERBB2) to activate signal transduction pathways and promote tumorigenesis and progression. Studies have shown that HER3 is not only associated with poor prognosis in non-small cell lung cancer (NSCLC), but also plays an important role in drug resistance in patients, making it a potential therapeutic target for NSCLC. Although no HER3-targeted therapy has been approved, several have entered clinical trials.This article describes the relevance of HER3 to NSCLC and the HER3-targeted therapy for NSCLC currently in clinical trials to provide reference for the research and development of HER3-targeted drugs.